Category 2 Peptide Reclassification: What April's Regulatory Shift Means

The April 23 Decision You've Probably Misunderstood

On April 23, a Category 2 reclassification triggered a compounding authority shift for seven peptide compounds. But here's what most providers got wrong: the regulatory decision had already been made before the meeting was scheduled. The committee vote didn't determine whether these peptides could be compounded. It formalized a decision made elsewhere—likely in regulatory agency workgroups months prior.

This distinction matters because it changes how you should interpret what actually happened and, more importantly, where real authority over peptide compounding now sits.

Understanding Category 2 and Compounding Authority

Category 2 classification in pharmaceutical regulation typically designates substances that:

• Have documented clinical evidence but limited FDA-approved indications
• Can be compounded under specific state pharmacy board oversight
• Require proper baseline and monitoring protocols
• Fall under state rather than federal compounding authority in many jurisdictions

The seven compounds affected by the April exit include several GH secretagogues and GHRH analogs commonly used in clinical practice. What the vote didn't do: eliminate compounding authority, ban peptides, or create a federal prohibition.

What it did do: formally recognize a reclassification that shifted oversight jurisdiction.

Where the Real Authority Actually Sits

This is the critical detail most commentary misses. The committee vote was essentially a rubber stamp. The substantive decision—whether these compounds would remain compoundable, under what conditions, and with what monitoring requirements—was made in regulatory agency channels before public discussion.

This means:

State boards of pharmacy now hold primary compounding authority for these peptides, not the federal committee.

Individual state regulations will govern whether a licensed pharmacist can compound these substances—and under what conditions.

Provider oversight becomes increasingly important because regulatory oversight shifted from a federal single-source authority to a distributed state-by-state model.

What This Means for Clinical Practice

If you're prescribing peptides, the April shift requires you to understand:

1. Your specific state's compounding rules. What's legal in Texas may differ from Florida or California. Check with your state board of pharmacy directly.

2. Pharmacist qualification requirements. Some states will likely require additional certifications or training for compounding peptides. Verify your pharmacy partner meets these standards.

3. Documentation and baseline testing. With regulatory oversight distributed to state boards, the burden shifts to your documentation. Baseline labs become non-negotiable:

   • Comprehensive metabolic panel (CMP)
   • Lipid panel
   • IGF-1 and fasting glucose
   • Thyroid function (TSH, free T4)
   • Testosterone (total and free) for male patients
   • Estradiol for female patients
   • Cortisol (morning, ideally 8 AM collection)
   • DHEA-S

4. Monitoring intervals matter more. Without unified federal oversight, your local jurisdiction may have specific requirements for follow-up testing. Plan for labs at 4-6 weeks, 12 weeks, and quarterly thereafter.

The Compounds Affected and Clinical Context

The seven substances in the Category 2 exit most likely include:

• GHRH analogs (tesamorelin, CJC-1295)
• GH secretagogues (ipamorelin, GHRP-6)
• IGF-1 related compounds

These remain clinically useful for:

• Age-related GH axis decline
• Metabolic resilience
• Body composition optimization when used with proper baseline testing
• Recovery and musculoskeletal support

But—and this is non-negotiable—their use requires the same rigor as any hormone therapy. Baseline testing is not optional. It's now your primary documentation shield in a decentralized regulatory environment.

What the Vote Won't Fix

The committee decision addresses regulatory pathway, not clinical efficacy, safety, or appropriate use. Problems it won't solve:

• Inadequate baseline testing. Providers still prescribe peptides without proper labs. The regulatory shift doesn't change what should be done.

• Lack of provider education. Knowing why you order specific tests (GH axis function, metabolic state, hormone balance) requires understanding endocrinology. Regulatory changes don't teach pharmacology.

• Access disparities. Some states may create barriers to compounding; others may remain permissive. Geographic inconsistency increases the likelihood of patients seeking non-prescribed sources.

• Monitoring compliance. Regulatory authority doesn't enforce patient follow-up. Quarterly labs still depend on patient engagement and provider diligence.

Your Action Items

Immediately:

• Verify your state's current compounding rules for Category 2 peptides
• Confirm your pharmacy partner's compliance with state regulations
• Review your baseline lab protocol

Ongoing:

• Implement mandatory baseline testing before any peptide prescription
• Document the clinical rationale (age-related decline, metabolic markers, etc.)
• Schedule follow-up labs at 4-6 weeks, 12 weeks, then quarterly
• Order full endocrine panels: IGF-1, testosterone (total/free), estradiol, TSH/free T4, DHEA-S, morning cortisol

Before Your Next Peptide Prescription:

• Understand the GH axis mechanism of action for the specific peptide
• Know what normal IGF-1 ranges are (typically 100–300 ng/mL, but context-dependent)
• Recognize red flags: IGF-1 > 350 ng/mL, fasting glucose > 110 mg/dL, TSH deviation

Bottom Line

The April 23 Category 2 exit formalized a decision made in regulatory backchannels. It shifted compounding authority from federal to state oversight, which means your documentation and your baseline testing protocols now matter more than ever. The vote changed jurisdiction, not clinical requirements. Peptides remain useful therapeutic tools, but they require the same evidence-based rigor as prescribed hormones. Know your state rules. Order the labs. Document the mechanism. Monitor quarterly. That's where real authority actually sits—in your clinical decision-making, not in a committee vote.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.